{
 "@context": "https://clearank.com/llms.txt",
 "@type": "clearank:AssetAnalysis",
 "url": "https://clearank.com/stock/crispr-therapeutics-crsp/",
 "dataUrl": "https://clearank.com/stock/crispr-therapeutics-crsp/data.json",
 "title": "Crispr Therapeutics AG (CRSP) Stock Forecast (2026)",
 "description": "Is CRISPR Therapeutics (CRSP) a Buy or Sell today? Get the AI price target, Casgevy revenue outlook and key risk levels. Updated daily.",
 "headline": "CRISPR Therapeutics AG (CRSP)",
 "published": "2026-08-21T09:25:39+00:00",
 "modified": "2026-09-11T18:07:32.586+00:00",
 "generated": "2026-09-11T21:16:25.282Z",
 "language": "en-US",
 "publisher": {
  "name": "CleaRank",
  "url": "https://clearank.com/"
 },
 "disclaimer": "Educational and informational only; not financial advice. AI-generated analysis reviewed by the CleaRank editorial team; prices delayed up to 15 minutes.",
 "asset": {
  "ticker": "CRSP",
  "name": "CRISPR Therapeutics AG",
  "type": "Common Stock",
  "exchange": "NASDAQ",
  "currency": "USD",
  "sector": "Healthcare",
  "industry": "Biotechnology",
  "country": "Switzerland",
  "website": "https://www.crisprtx.com"
 },
 "quote": {
  "price": 52.16,
  "previousClose": 52.26,
  "change": -0.1,
  "changePercent": -0.19,
  "open": 52.68,
  "high": 53.21,
  "low": 51.95,
  "volume": 15631,
  "averageVolume": 1081557,
  "marketCap": 5053158045,
  "fiftyTwoWeekHigh": 78.48,
  "fiftyTwoWeekLow": 44.12,
  "marketOpen": false,
  "asOf": "2026-09-11T18:07:31.000Z"
 },
 "statistics": {
  "pe": -8.061823802163833,
  "eps": -4.71,
  "dividendYield": 0,
  "beta": 1.76,
  "priceToSales": 377.3266,
  "priceToBook": 2.8922462,
  "revenueTtm": 13392000,
  "grossMargin": -3.0272,
  "returnOnEquity": -0.26095
 },
 "technicals": {
  "rsi": 26.28,
  "macd": -0.01,
  "sma50": 53.58,
  "sma200": 53.28,
  "rsiSignal": "Oversold",
  "trend": "Neutral",
  "pricePosition": "Bearish",
  "macdSignal": "Neutral",
  "rating": "Bearish"
 },
 "analysis": {
  "rating": "Hold",
  "score": 59,
  "consensus": "Hold",
  "fairValue": 77.89,
  "analystTarget": 80,
  "analystCount": 22,
  "wallStreetConsensus": "Hold",
  "generatedAt": "2026-09-11T18:07:31.000Z",
  "priceAtAnalysis": 52.16,
  "volatility": {
   "daily": 3.52,
   "risk": "volatile"
  }
 },
 "tradePlan": {
  "bias": "Neutral",
  "conservativeEntry": 51.64,
  "aggressiveEntry": 52.16,
  "stopLoss": 48.64,
  "stopLossPercent": 5.8,
  "targets": [
   53.19,
   54.22,
   55.77
  ]
 },
 "projections": {
  "basis": "Monte Carlo simulation on historical return distribution, re-run daily; not price targets",
  "years": [
   {
    "year": 2027,
    "downside10th": 30.38,
    "base": 57.66,
    "upside90th": 109.44
   },
   {
    "year": 2028,
    "downside10th": 25.75,
    "base": 63.74,
    "upside90th": 157.75
   },
   {
    "year": 2029,
    "downside10th": 23.22,
    "base": 70.46,
    "upside90th": 213.78
   },
   {
    "year": 2030,
    "downside10th": 21.62,
    "base": 77.89,
    "upside90th": 280.59
   },
   {
    "year": 2031,
    "downside10th": 20.55,
    "base": 86.1,
    "upside90th": 360.84
   },
   {
    "year": 2032,
    "downside10th": 19.81,
    "base": 95.18,
    "upside90th": 457.35
   },
   {
    "year": 2033,
    "downside10th": 19.31,
    "base": 105.22,
    "upside90th": 573.33
   },
   {
    "year": 2034,
    "downside10th": 18.99,
    "base": 116.32,
    "upside90th": 712.49
   },
   {
    "year": 2035,
    "downside10th": 18.81,
    "base": 128.58,
    "upside90th": 879.15
   },
   {
    "year": 2036,
    "downside10th": 18.74,
    "base": 142.14,
    "upside90th": 1078.36
   }
  ]
 },
 "faqCount": 7,
 "sources": [
  "TwelveData",
  "Wall Street consensus"
 ],
 "sections": [
  {
   "id": "price",
   "title": "CRSP Price Analysis"
  },
  {
   "id": "market-metrics",
   "title": "Market Metrics",
   "facts": {
    "Open": "$52.68",
    "Day Range": "$51.95 to $53.21",
    "Prev Close": "$52.26",
    "Volume": "15.6K",
    "52-Week Range": "$44.12 to $78.48",
    "Market Cap": "$5.05B"
   }
  },
  {
   "id": "peer-benchmarking",
   "title": "Peer Benchmarking",
   "text": [
    "Sector Position Analysis On price-to-sales, the yardstick used here in place of P/E, CRSP trades at 377.33x, far above the sector average of 4.20x."
   ]
  },
  {
   "id": "analysis",
   "title": "CRSP Analysis",
   "text": [
    "CRISPR Therapeutics AG (CRSP) is currently exhibiting bearish momentum, with its Relative Strength Index (RSI) at 26.28, indicating an oversold condition. The stock is trading below its 50-day and 200-day moving averages ($53.58 and $53.28), reinforcing the downward trend. The MACD is slightly negative at -0.007, further supporting the bearish sentiment. Key support levels are being tested, and the current price action suggests potential for a near-term bounce given the oversold RSI. However, until CRSP can reclaim its 50-day and 200-day moving averages, the overall technical picture remains weak. Volume has been significantly below average recently, suggesting a lack of conviction in the current price action.",
    "Insiders have demonstrated strong conviction by purchasing $52.7 million in stock versus $19.5 million in sales, signaling confidence in the company's future prospects.",
    "CRISPR Therapeutics AG has reported exceptional revenue growth of 1041.4%, with next year's revenue projected to increase by 283.00%, indicating significant market traction and expansion potential.",
    "The median analyst price target of $80.00 suggests a potential upside of 53.4% from the current stock price of $52.16, indicating Wall Street's belief in future appreciation.",
    "CRSP is trading below its 50-day and 200-day moving averages ($53.58 and $53.28), with an oversold RSI of 26.28, indicating bearish momentum that could persist in the short term.",
    "The company currently has a negative EPS of -4.71, highlighting ongoing profitability challenges that could weigh on valuation and investor sentiment.",
    "CRISPR Therapeutics AG (CRSP) is positioned for significant long-term growth, driven by its pioneering gene-editing technology and substantial revenue expansion. The base case scenario anticipates the stock to move towards its median analyst price target of $80.00 within the next 6-12 months, representing a potential upside of over 53%. This outlook is supported by strong insider conviction and promising forward revenue estimates. However, the trajectory could be altered by several factors. Upside catalysts include successful clinical trial results and regulatory approvals, which could significantly boost investor confidence and valuation. Conversely, downside risks include continued unprofitability, potential setbacks in clinical development, increased competition within the gene-editing space, and broader sector headwinds. The current oversold technical conditions may offer a near-term bounce, but sustained recovery will depend on fundamental improvements and overcoming existing bearish technicals."
   ],
   "lists": {
    "ProTips": [
     "Given the current oversold RSI and strong insider buying, consider monitoring CRSP for potential entry points as it consolidates or shows signs of a technical reversal.",
     "The significant revenue growth and future projections for CRISPR Therapeutics AG warrant close attention to clinical trial progress and regulatory milestones as key drivers of future performance.",
     "As a company in the highly innovative but volatile Biotechnology sector, maintain a diversified portfolio and consider position sizing carefully to manage the inherent risk associated with companies like CRSP."
    ]
   },
   "catalysts": [
    {
     "type": "Bullish",
     "title": "Insider Net Buying Activity",
     "text": "Insiders have demonstrated strong conviction by purchasing $52.7 million in stock versus $19.5 million in sales, signaling confidence in the company's future prospects.",
     "source": "Insider Trading Data"
    },
    {
     "type": "Bullish",
     "title": "Strong Revenue Growth and Projections",
     "text": "CRISPR Therapeutics AG has reported exceptional revenue growth of 1041.4%, with next year's revenue projected to increase by 283.00%, indicating significant market traction and expansion potential.",
     "source": "Wall Street Revenue Estimates"
    },
    {
     "type": "Bullish",
     "title": "Median Analyst Price Target Upside",
     "text": "The median analyst price target of $80.00 suggests a potential upside of 53.4% from the current stock price of $52.16, indicating Wall Street's belief in future appreciation.",
     "source": "Wall Street Summary"
    },
    {
     "type": "Bearish",
     "title": "Bearish Technical Trend",
     "text": "CRSP is trading below its 50-day and 200-day moving averages ($53.58 and $53.28), with an oversold RSI of 26.28, indicating bearish momentum that could persist in the short term.",
     "source": "Technical Analysis Data"
    },
    {
     "type": "Bearish",
     "title": "Lack of Profitability",
     "text": "The company currently has a negative EPS of -4.71, highlighting ongoing profitability challenges that could weigh on valuation and investor sentiment.",
     "source": "Fundamental Analysis Data"
    }
   ]
  },
  {
   "id": "key-statistics",
   "title": "Key Statistics",
   "text": [
    "CRISPR Therapeutics AG (CRSP) presents a mixed fundamental picture, with a negative EPS of -4.71 rendering its P/E ratio mathematically negative, indicating it is not yet profitable on a per-share basis. Despite this, the company has demonstrated exceptional revenue growth of 1041.4% (from a very low base), and forward estimates project continued strong growth, with next year's revenue expected to increase by 283.00%. The current price of $52.16 is well below the median analyst price target of $80.00, suggesting potential undervaluation relative to future growth expectations. While the company's high revenue growth is a positive indicator, the lack of profitability and the significant upside potential implied by the analyst target price suggest that investors are pricing in substantial future success. The balance sheet strength and cash position would be critical to assess for long-term viability, especially given the current negative EPS. The company operates in the Biotechnology sector, which often requires significant R&D investment before achieving profitability.",
    "CRISPR Therapeutics AG (CRSP) most recently reported an EPS of $0.89 for July 2026, beating the estimate of $0.87 by 2.3%, and the stock saw a 0.19% price increase following the announcement. Prior to this, the company reported a loss of -$1.28 in May 2026, missing estimates by 4.07%. The earnings trend shows a pattern of mixed results, with some quarters showing beats and others misses, but the most recent quarter indicates a positive step towards profitability.",
    "CRISPR Therapeutics AG (CRSP) faces significant risks, including its current lack of profitability, as indicated by its negative EPS. The stock is also trading below key moving averages, signaling bearish technical momentum that could persist. Also, the Biotechnology sector is inherently volatile and subject to regulatory hurdles and lengthy development cycles, which could impact future growth and profitability."
   ],
   "tables": [
    {
     "caption": "",
     "columns": [],
     "rows": [
      {
       "label": "Market Cap",
       "cells": [
        "5.05B"
       ]
      },
      {
       "label": "P/E Ratio",
       "cells": [
        "N/A (Negative EPS)"
       ]
      },
      {
       "label": "EPS (TTM)",
       "cells": [
        "-4.71"
       ]
      },
      {
       "label": "Dividend Yield",
       "cells": [
        "0.00%"
       ]
      },
      {
       "label": "52 Week High",
       "cells": [
        "78.48"
       ]
      },
      {
       "label": "52 Week Low",
       "cells": [
        "44.12"
       ]
      }
     ]
    }
   ]
  },
  {
   "id": "technical-indicators",
   "title": "Technical Indicators",
   "text": [
    "Technical Rating Bearish RSI Oversold SMA Cross Neutral Price vs SMA Bearish MACD Neutral Price is trading below the 50-day SMA, RSI at 26.3 suggests oversold conditions; potential bounce setup."
   ],
   "facts": {
    "RSI": "Oversold",
    "SMA Cross": "Neutral",
    "Price vs SMA": "Bearish",
    "MACD": "Neutral"
   },
   "tables": [
    {
     "caption": "",
     "columns": [],
     "rows": [
      {
       "label": "RSI (14)",
       "cells": [
        "26.28"
       ]
      },
      {
       "label": "MACD",
       "cells": [
        "-0.01"
       ]
      },
      {
       "label": "SMA 50",
       "cells": [
        "53.58"
       ]
      },
      {
       "label": "SMA 200",
       "cells": [
        "53.28"
       ]
      }
     ]
    }
   ]
  },
  {
   "id": "correlations",
   "title": "Market Correlations",
   "text": [
    "How this stock moves relative to other assets",
    "Based on 1 year of daily price data. Correlations may vary over different time periods."
   ],
   "facts": {
    "Correlation with S&P 500 (SPY)": "+0.41",
    "Correlation with Nasdaq 100 (QQQ)": "+0.40",
    "Correlation with Bitcoin (BTC)": "+0.16",
    "Correlation with Gold (XAU)": "+0.16"
   }
  },
  {
   "id": "trade-plans",
   "title": "CRSP Trade Plans",
   "text": [
    "Specific entry, exit, and risk management levels",
    "Enter now if confident",
    "Volatility-Adjusted Stop Loss Calculated based on RSI (26.3) and current market volatility",
    "Consider scaling out: Take 50% profit at Target 1, 30% at Target 2, let 20% run to Target 3"
   ],
   "facts": {
    "TARGET 1": "$53.19",
    "TARGET 2": "$54.22",
    "TARGET 3": "$55.77",
    "STOP LOSS": "$48.64"
   }
  },
  {
   "id": "risk",
   "title": "Risk & Volatility",
   "facts": {
    "Daily Volatility": "3.52%"
   },
   "lists": {
    "Risk considerations": [
     "Monitor position sizing based on current volatility levels",
     "Consider stop-loss placement beyond recent price range",
     "Diversification helps mitigate single-stock risk exposure"
    ]
   }
  },
  {
   "id": "growth",
   "title": "Growth of $10,000",
   "text": [
    "A $10,000 investment in CRSP in October 2016 would be worth about $37,090 today, compared with about $35,366 for the same investment in the S&P 500 benchmark."
   ]
  },
  {
   "id": "monte-carlo",
   "title": "Monte Carlo Projection (10yr)",
   "text": [
    "CleaRank's 10-year Monte Carlo simulation projects that a $10,000 investment in CRSP today could grow to about $27,251 by 2036 in the base case, with a bull case near $206,740 and a bear case around $3,592. Projections are statistical simulations, not guarantees."
   ]
  },
  {
   "id": "price-prediction",
   "title": "CRSP Stock Price Prediction: 2030",
   "text": [
    "CleaRank's simulation projects a price near $77.89 for CRSP by 2030 in the base case, from $52.16 today (1.5x over 4 years). The downside path ends near $21.62. These are outcomes of a Monte Carlo simulation run on CRSP's historical return distribution, not price targets, and they assume no dividends are reinvested.",
    "Method: 10,000 simulated price paths using CRSP's historical volatility and drift, re-run daily. The base case is the median path; the two outer columns are the 10th and 90th percentile outcomes, which widen with time because uncertainty compounds. CRSP is highly volatile, so its upside column reaches an extreme multiple; treat it as a statistical tail, not an expectation. Simulations are not guarantees, and past volatility does not predict future returns. This is analysis, not investment advice."
   ],
   "tables": [
    {
     "caption": "CRSP simulated price paths by year",
     "columns": [
      "Year",
      "Downside (10th pct)",
      "Base case",
      "Upside (90th pct)"
     ],
     "rows": [
      {
       "label": "2027",
       "cells": [
        "$30.38",
        "$57.66",
        "$109"
       ]
      },
      {
       "label": "2028",
       "cells": [
        "$25.75",
        "$63.74",
        "$158"
       ]
      },
      {
       "label": "2029",
       "cells": [
        "$23.22",
        "$70.46",
        "$214"
       ]
      },
      {
       "label": "2030",
       "cells": [
        "$21.62",
        "$77.89",
        "$281"
       ]
      },
      {
       "label": "2031",
       "cells": [
        "$20.55",
        "$86.10",
        "$361"
       ]
      },
      {
       "label": "2032",
       "cells": [
        "$19.81",
        "$95.18",
        "$457"
       ]
      },
      {
       "label": "2033",
       "cells": [
        "$19.31",
        "$105",
        "$573"
       ]
      },
      {
       "label": "2034",
       "cells": [
        "$18.99",
        "$116",
        "$712"
       ]
      },
      {
       "label": "2035",
       "cells": [
        "$18.81",
        "$129",
        "$879"
       ]
      },
      {
       "label": "2036",
       "cells": [
        "$18.74",
        "$142",
        "$1,078"
       ]
      }
     ]
    }
   ]
  },
  {
   "id": "people-also-watch",
   "title": "People Also Watch",
   "links": [
    {
     "text": "OFIX Orthofix Medical Inc. NASDAQ $8.91 +2.53%",
     "url": "https://clearank.com/stock/ofix-stock-analysis/"
    },
    {
     "text": "NVO Novo Nordisk A/S Sponsored NYSE $43.07 -2.15%",
     "url": "https://clearank.com/stock/novo-nordisk-nvo/"
    },
    {
     "text": "CRNX Crinetics Pharmaceuticals, Inc. NASDAQ $84.95 +0.00%",
     "url": "https://clearank.com/stock/crinetics-pharmaceuticals-crnx/"
    },
    {
     "text": "OSCR Oscar Health, Inc. NYSE $31.84 +0.2361%",
     "url": "https://clearank.com/stock/oscr-stock-analysis/"
    },
    {
     "text": "IDXX IDEXX Laboratories, Inc. NASDAQ $504.59 -0.3830%",
     "url": "https://clearank.com/stock/idxx-stock-analysis/"
    },
    {
     "text": "CVS CVS Health Corporation NYSE $94.67 -0.6506%",
     "url": "https://clearank.com/stock/cvs-health-cvs/"
    },
    {
     "text": "MCK McKesson Corporation NYSE $880.86 -1.21%",
     "url": "https://clearank.com/stock/mck-stock-analysis/"
    },
    {
     "text": "NEOG Neogen Corp. NASDAQ $11.81 +0.3398%",
     "url": "https://clearank.com/stock/neogen-neog/"
    }
   ]
  },
  {
   "id": "related-comparisons",
   "title": "Popular Comparisons",
   "links": [
    {
     "text": "UBER vs LYFT Comparison Head-to-head analysis →",
     "url": "https://clearank.com/compare/uber-vs-lyft/"
    },
    {
     "text": "VGT vs SCHG Comparison Head-to-head analysis →",
     "url": "https://clearank.com/compare/vgt-vs-schg/"
    },
    {
     "text": "VUG vs VGT Comparison Head-to-head analysis →",
     "url": "https://clearank.com/compare/vug-vs-vgt/"
    }
   ]
  },
  {
   "id": "insider-trading",
   "title": "CRSP Insider Trading Analysis",
   "facts": {
    "Bought": "$52.7M",
    "Sold": "$19.5M",
    "Insiders": "8",
    "Avg Transaction": "$2.3M"
   },
   "tables": [
    {
     "caption": "Recent insider transactions in CRSP",
     "columns": [
      "Date",
      "Insider",
      "Type",
      "Shares",
      "Value"
     ],
     "rows": [
      {
       "label": "May 14, 2018",
       "cells": [
        "EMSTER KURT VON Director",
        "Sell",
        "650.0K",
        "$35.4M"
       ]
      },
      {
       "label": "Dec 7, 2020",
       "cells": [
        "BOLZON BRADLEY J Director",
        "Sell",
        "171.0K",
        "$26.4M"
       ]
      },
      {
       "label": "Feb 19, 2021",
       "cells": [
        "BOLZON BRADLEY J Director",
        "Sell",
        "171.0K",
        "$25.5M"
       ]
      },
      {
       "label": "Dec 4, 2017",
       "cells": [
        "CELGENE CORP Beneficial Owner of more than 10% of a Class of Security",
        "Sell",
        "1.1M",
        "$21.1M"
       ]
      },
      {
       "label": "Mar 23, 2021",
       "cells": [
        "KLEIN LAWRENCE OTTO Chairman of the Board",
        "Sell",
        "100.0K",
        "$12.8M"
       ]
      },
      {
       "label": "Nov 30, 2020",
       "cells": [
        "NOVAK RODGER President",
        "Sell",
        "100.0K",
        "$12.5M"
       ]
      },
      {
       "label": "Apr 27, 2018",
       "cells": [
        "BOLZON BRADLEY J Director",
        "Sell",
        "222.3K",
        "$11.1M"
       ]
      },
      {
       "label": "Apr 27, 2018",
       "cells": [
        "WOIWODE THOMAS Director",
        "Sell",
        "222.3K",
        "$11.1M"
       ]
      },
      {
       "label": "Jun 29, 2021",
       "cells": [
        "BOLZON BRADLEY J Director",
        "Sell",
        "47.5K",
        "$7.1M"
       ]
      },
      {
       "label": "May 8, 2018",
       "cells": [
        "BOLZON BRADLEY J Director",
        "Sell",
        "129.0K",
        "$6.5M"
       ]
      }
     ]
    }
   ],
   "links": [
    {
     "text": "SEC Form 4",
     "url": "https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&company=CRISPR+Therapeutics+AG&type=4&dateb=&owner=include&count=40&search_text=&action=getcompany"
    }
   ]
  },
  {
   "id": "faq",
   "title": "Frequently Asked Questions"
  }
 ],
 "faq": [
  {
   "question": "What is CRISPR Therapeutics AG's stock price prediction for 2030?",
   "answer": "CRISPR Therapeutics AG's stock price is projected to be $77.89 by 2030 based on a Monte Carlo simulation's base case. The downside projection is $21.62, while the upside projection reaches $280.59. These figures represent statistical simulation outcomes, not guaranteed price targets."
  },
  {
   "question": "Is CRISPR Therapeutics AG stock a buy right now?",
   "answer": "CRISPR Therapeutics AG (CRSP) is currently rated a 'Hold' by Wall Street analysts, with a median price target of $80.00, suggesting a potential 53.4% upside from its current price of $52.16. While insider sentiment is positive and revenue growth is strong, the stock is trading below its key moving averages, indicating bearish technical momentum."
  },
  {
   "question": "What are the biggest risks facing CRISPR Therapeutics AG?",
   "answer": "The primary risks for CRISPR Therapeutics AG include its current unprofitability, evidenced by a negative EPS, and its bearish technical trend, trading below key moving averages. The volatile nature of the Biotechnology sector, with its regulatory challenges and long development timelines, also poses a significant risk."
  },
  {
   "question": "How is CRISPR Therapeutics AG performing financially?",
   "answer": "CRISPR Therapeutics AG has demonstrated exceptional revenue growth of 1041.4% (from a very low base) and projects further strong growth for next year. However, the company currently has a negative EPS of -4.71, indicating it is not yet profitable."
  },
  {
   "question": "What is the Wall Street consensus for CRISPR Therapeutics AG?",
   "answer": "The Wall Street consensus for CRISPR Therapeutics AG (CRSP) is 'Hold', with a score of 70 out of 100. This is based on 22 analysts, with 5 rating it 'Strong Buy', 8 'Buy', and 9 'Hold'."
  },
  {
   "question": "What is CRISPR Therapeutics AG's current technical standing?",
   "answer": "CRISPR Therapeutics AG (CRSP) is currently in an oversold technical position with an RSI at 26.3. The stock is trading below its 50-day and 200-day moving averages ($53.58 and $53.28), indicating bearish momentum, though the oversold condition may suggest a potential for a bounce."
  },
  {
   "question": "Are insiders buying or selling CRISPR Therapeutics AG stock?",
   "answer": "Insiders at CRISPR Therapeutics AG are net buyers, having purchased $52.7 million worth of stock compared to $19.5 million in sales. This 'Moderate Buy Signal' suggests a positive sentiment from management regarding the company's future."
  }
 ],
 "related": {
  "peopleAlsoWatch": [
   {
    "ticker": "OFIX",
    "name": "Orthofix Medical Inc. NASDAQ",
    "price": "$8.91",
    "change": "+2.53%",
    "url": "https://clearank.com/stock/ofix-stock-analysis/"
   },
   {
    "ticker": "NVO",
    "name": "Novo Nordisk A/S Sponsored NYSE",
    "price": "$43.07",
    "change": "-2.15%",
    "url": "https://clearank.com/stock/novo-nordisk-nvo/"
   },
   {
    "ticker": "CRNX",
    "name": "Crinetics Pharmaceuticals, Inc. NASDAQ",
    "price": "$84.95",
    "change": "+0.00%",
    "url": "https://clearank.com/stock/crinetics-pharmaceuticals-crnx/"
   },
   {
    "ticker": "OSCR",
    "name": "Oscar Health, Inc. NYSE",
    "price": "$31.84",
    "change": "+0.2361%",
    "url": "https://clearank.com/stock/oscr-stock-analysis/"
   },
   {
    "ticker": "IDXX",
    "name": "IDEXX Laboratories, Inc. NASDAQ",
    "price": "$504.59",
    "change": "-0.3830%",
    "url": "https://clearank.com/stock/idxx-stock-analysis/"
   },
   {
    "ticker": "CVS",
    "name": "CVS Health Corporation NYSE",
    "price": "$94.67",
    "change": "-0.6506%",
    "url": "https://clearank.com/stock/cvs-health-cvs/"
   },
   {
    "ticker": "MCK",
    "name": "McKesson Corporation NYSE",
    "price": "$880.86",
    "change": "-1.21%",
    "url": "https://clearank.com/stock/mck-stock-analysis/"
   },
   {
    "ticker": "NEOG",
    "name": "Neogen Corp. NASDAQ",
    "price": "$11.81",
    "change": "+0.3398%",
    "url": "https://clearank.com/stock/neogen-neog/"
   }
  ],
  "comparisons": [
   {
    "ticker": "UBER vs LYFT Comparison",
    "name": "",
    "url": "https://clearank.com/compare/uber-vs-lyft/"
   },
   {
    "ticker": "VGT vs SCHG Comparison",
    "name": "",
    "url": "https://clearank.com/compare/vgt-vs-schg/"
   },
   {
    "ticker": "VUG vs VGT Comparison",
    "name": "",
    "url": "https://clearank.com/compare/vug-vs-vgt/"
   }
  ],
  "sectorHub": {
   "text": "Browse all Healthcare →",
   "url": "https://clearank.com/sector/healthcare/"
  },
  "Newly Tracked": [
   {
    "ticker": "ILMN",
    "text": "Illumina Inc.",
    "url": "https://clearank.com/stock/ilmn-stock-analysis/"
   },
   {
    "ticker": "KMB",
    "text": "Kimberly-Clark Corporation",
    "url": "https://clearank.com/stock/kmb-stock-analysis/"
   },
   {
    "ticker": "IAUM",
    "text": "iShares Gold Trust Micro",
    "url": "https://clearank.com/etf/iaum-etf-analysis/"
   },
   {
    "ticker": "SLVR",
    "text": "Sprott Silver Miners & Physical Silver ETF",
    "url": "https://clearank.com/etf/slvr-etf-analysis/"
   },
   {
    "ticker": "NTES",
    "text": "NetEase, Inc.",
    "url": "https://clearank.com/stock/ntes-stock-analysis/"
   }
  ],
  "Top Movers (24h)": [
   {
    "ticker": "EIGEN/USD",
    "text": "↑ 9.39%",
    "url": "https://clearank.com/crypto/eigen-usd-crypto-analysis/"
   },
   {
    "ticker": "EGLD/USD",
    "text": "↓ 9.23%",
    "url": "https://clearank.com/crypto/egld-usd-crypto-analysis/"
   },
   {
    "ticker": "AERO/USD",
    "text": "↑ 8.90%",
    "url": "https://clearank.com/crypto/aero-usd-crypto-analysis/"
   },
   {
    "ticker": "HUT",
    "text": "↑ 8.77%",
    "url": "https://clearank.com/stock/hut-stock-analysis/"
   },
   {
    "ticker": "MRNA",
    "text": "↑ 8.44%",
    "url": "https://clearank.com/stock/moderna-mrna/"
   }
  ],
  "Also in Healthcare": [
   {
    "ticker": "BNTX",
    "text": "BioNTech SE",
    "url": "https://clearank.com/stock/bntx-stock-analysis/"
   },
   {
    "ticker": "CAPR",
    "text": "Capricor Therapeutics, Inc.",
    "url": "https://clearank.com/stock/capr-stock-analysis/"
   },
   {
    "ticker": "CRNX",
    "text": "Crinetics Pharmaceuticals",
    "url": "https://clearank.com/stock/crinetics-pharmaceuticals-crnx/"
   },
   {
    "ticker": "FBRX",
    "text": "Forte",
    "url": "https://clearank.com/stock/fbrx-stock-analysis/"
   },
   {
    "ticker": "IONS",
    "text": "Ionis",
    "url": "https://clearank.com/stock/ions-stock-analysis/"
   }
  ]
 },
 "schema": [
  {
   "@context": "https://schema.org",
   "@graph": [
    {
     "@type": "Place",
     "@id": "https://clearank.com/#place",
     "address": {
      "@type": "PostalAddress",
      "streetAddress": "Beni Berman 2",
      "addressLocality": "Netanya",
      "addressRegion": "Center",
      "postalCode": "4249330",
      "addressCountry": "IL"
     }
    },
    {
     "@type": "Organization",
     "@id": "https://clearank.com/#organization",
     "name": "CleaRank",
     "url": "https://clearank.com",
     "sameAs": [
      "https://twitter.com/CleaRank",
      "https://www.linkedin.com/company/clearank/",
      "https://www.youtube.com/@CleaRank"
     ],
     "email": "info@clearank.com",
     "address": {
      "@type": "PostalAddress",
      "streetAddress": "Beni Berman 2",
      "addressLocality": "Netanya",
      "addressRegion": "Center",
      "postalCode": "4249330",
      "addressCountry": "IL"
     },
     "logo": {
      "@type": "ImageObject",
      "@id": "https://clearank.com/#logo",
      "url": "https://clearank.com/wp-content/uploads/2025/02/CleaRank-Logo-e1738621466340.jpg",
      "contentUrl": "https://clearank.com/wp-content/uploads/2025/02/CleaRank-Logo-e1738621466340.jpg",
      "caption": "CleaRank",
      "inLanguage": "en-US",
      "width": "336",
      "height": "153"
     },
     "description": "The CleaRank vision is to bring clarity to the online trading industry and protect trader interests. We use our proprietary technology, expert analysis and verified trader insights, to deliver data driven broker evaluations you can trust. Our CLEAR™ Score is our foundation, a transparent, unbiased methodology that assesses brokers and firms based on the most critical factors including regulation, fees, platform reliability, and real user experiences. We are here to change an unfair system and unlike other review sites that are influenced by partnerships or subjective opinions, CleaRank is 100% independent–abiding by our rigorous CLEAR™ editorial code. We do not accept financial incentives from brokers, so what you see is what you get with no hidden agendas, just honest, actionable feedback. Clear data. Honest reviews. That's the CleaRank promise",
     "numberOfEmployees": {
      "@type": "QuantitativeValue",
      "value": "40"
     },
     "location": {
      "@id": "https://clearank.com/#place"
     }
    },
    {
     "@type": "WebSite",
     "@id": "https://clearank.com/#website",
     "url": "https://clearank.com",
     "name": "CleaRank",
     "publisher": {
      "@id": "https://clearank.com/#organization"
     },
     "inLanguage": "en-US"
    },
    {
     "@type": "ImageObject",
     "@id": "https://clearank.com/wp-content/uploads/2026/08/CRSP-crispr-therapeutics-analysis-2026-08.png",
     "url": "https://clearank.com/wp-content/uploads/2026/08/CRSP-crispr-therapeutics-analysis-2026-08.png",
     "width": "1280",
     "height": "720",
     "caption": "CRISPR Therapeutics AG (CRSP) stock price analysis chart for August 2026",
     "inLanguage": "en-US"
    },
    {
     "@type": "BreadcrumbList",
     "@id": "https://clearank.com/stock/crispr-therapeutics-crsp/#breadcrumb",
     "itemListElement": [
      {
       "@type": "ListItem",
       "position": "1",
       "item": {
        "@id": "https://clearank.com",
        "name": "Home"
       }
      },
      {
       "@type": "ListItem",
       "position": "2",
       "item": {
        "@id": "https://clearank.com/stock/crispr-therapeutics-crsp/",
        "name": "CRISPR Therapeutics AG (CRSP) Stock Analysis"
       }
      }
     ]
    },
    {
     "@type": "WebPage",
     "@id": "https://clearank.com/stock/crispr-therapeutics-crsp/#webpage",
     "url": "https://clearank.com/stock/crispr-therapeutics-crsp/",
     "name": "Crispr Therapeutics AG (CRSP) Stock Forecast (2026)",
     "datePublished": "2026-08-21T09:25:39+00:00",
     "dateModified": "2026-09-11T18:07:32+00:00",
     "isPartOf": {
      "@id": "https://clearank.com/#website"
     },
     "primaryImageOfPage": {
      "@id": "https://clearank.com/wp-content/uploads/2026/08/CRSP-crispr-therapeutics-analysis-2026-08.png"
     },
     "inLanguage": "en-US",
     "breadcrumb": {
      "@id": "https://clearank.com/stock/crispr-therapeutics-crsp/#breadcrumb"
     }
    },
    {
     "@type": "Organization",
     "@id": "https://clearank.com/writer/clearank/",
     "name": "CleaRank",
     "description": "CleaRank's vision is to bring clarity to the online trading industry and protecting trader interests by delivering data-driven broker evaluations you can trust.",
     "url": "https://clearank.com/writer/clearank/",
     "image": {
      "@type": "ImageObject",
      "@id": "https://secure.gravatar.com/avatar/4900cf75f960a22a21f1c864e98abc4d5285fa159ea1025d0e8a9db5136e28ef?s=96&d=mm&r=g",
      "url": "https://secure.gravatar.com/avatar/4900cf75f960a22a21f1c864e98abc4d5285fa159ea1025d0e8a9db5136e28ef?s=96&d=mm&r=g",
      "caption": "CleaRank",
      "inLanguage": "en-US"
     },
     "sameAs": [
      "https://clearank.com/",
      "https://twitter.com/CleaRank",
      "https://www.linkedin.com/company/clearank/",
      "https://www.youtube.com/@CleaRank"
     ],
     "worksFor": {
      "@id": "https://clearank.com/#organization"
     },
     "logo": "https://clearank.com/wp-content/uploads/2025/02/CleaRank-Logo-e1738621466340.jpg"
    },
    {
     "@type": "Article",
     "headline": "Crispr Therapeutics AG (CRSP) Stock Forecast (2026)",
     "datePublished": "2026-08-21T09:25:39+00:00",
     "dateModified": "2026-09-11T18:07:32+00:00",
     "author": {
      "@id": "https://clearank.com/writer/clearank/",
      "name": "CleaRank"
     },
     "publisher": {
      "@id": "https://clearank.com/#organization"
     },
     "description": "Is CRISPR Therapeutics (CRSP) a Buy or Sell today? Get the AI price target, Casgevy revenue outlook and key risk levels. Updated daily.",
     "name": "Crispr Therapeutics AG (CRSP) Stock Forecast (2026)",
     "@id": "https://clearank.com/stock/crispr-therapeutics-crsp/#richSnippet",
     "isPartOf": {
      "@id": "https://clearank.com/stock/crispr-therapeutics-crsp/#webpage"
     },
     "image": {
      "@id": "https://clearank.com/wp-content/uploads/2026/08/CRSP-crispr-therapeutics-analysis-2026-08.png"
     },
     "inLanguage": "en-US",
     "mainEntityOfPage": {
      "@id": "https://clearank.com/stock/crispr-therapeutics-crsp/#webpage"
     }
    }
   ]
  },
  {
   "@context": "https://schema.org",
   "@type": "FinancialProduct",
   "name": "CRISPR Therapeutics AG (CRSP)",
   "tickerSymbol": "CRSP",
   "url": "https://clearank.com/stock/crispr-therapeutics-crsp/",
   "description": "AI-powered financial analysis for CRISPR Therapeutics AG (CRSP) including technical indicators, market metrics, valuation, and price targets - refreshed daily by CleaRank Financial AI.",
   "exchange": "NASDAQ",
   "offers": {
    "@type": "Offer",
    "price": 52.16,
    "priceCurrency": "USD",
    "availability": "https://schema.org/InStock",
    "url": "https://clearank.com/stock/crispr-therapeutics-crsp/",
    "priceValidUntil": "2026-09-12"
   }
  },
  {
   "@context": "https://schema.org",
   "@type": "FAQPage",
   "mainEntity": [
    {
     "@type": "Question",
     "name": "What is CRISPR Therapeutics AG's stock price prediction for 2030?",
     "acceptedAnswer": {
      "@type": "Answer",
      "text": "CRISPR Therapeutics AG's stock price is projected to be $77.89 by 2030 based on a Monte Carlo simulation's base case. The downside projection is $21.62, while the upside projection reaches $280.59. These figures represent statistical simulation outcomes, not guaranteed price targets."
     }
    },
    {
     "@type": "Question",
     "name": "Is CRISPR Therapeutics AG stock a buy right now?",
     "acceptedAnswer": {
      "@type": "Answer",
      "text": "CRISPR Therapeutics AG (CRSP) is currently rated a 'Hold' by Wall Street analysts, with a median price target of $80.00, suggesting a potential 53.4% upside from its current price of $52.16. While insider sentiment is positive and revenue growth is strong, the stock is trading below its key moving averages, indicating bearish technical momentum."
     }
    },
    {
     "@type": "Question",
     "name": "What are the biggest risks facing CRISPR Therapeutics AG?",
     "acceptedAnswer": {
      "@type": "Answer",
      "text": "The primary risks for CRISPR Therapeutics AG include its current unprofitability, evidenced by a negative EPS, and its bearish technical trend, trading below key moving averages. The volatile nature of the Biotechnology sector, with its regulatory challenges and long development timelines, also poses a significant risk."
     }
    },
    {
     "@type": "Question",
     "name": "How is CRISPR Therapeutics AG performing financially?",
     "acceptedAnswer": {
      "@type": "Answer",
      "text": "CRISPR Therapeutics AG has demonstrated exceptional revenue growth of 1041.4% and projects further strong growth for next year. However, the company currently has a negative EPS of -4.71, indicating it is not yet profitable."
     }
    },
    {
     "@type": "Question",
     "name": "What is the Wall Street consensus for CRISPR Therapeutics AG?",
     "acceptedAnswer": {
      "@type": "Answer",
      "text": "The Wall Street consensus for CRISPR Therapeutics AG (CRSP) is 'Hold', with a score of 70 out of 100. This is based on 22 analysts, with 5 rating it 'Strong Buy', 8 'Buy', and 9 'Hold'."
     }
    },
    {
     "@type": "Question",
     "name": "What is CRISPR Therapeutics AG's current technical standing?",
     "acceptedAnswer": {
      "@type": "Answer",
      "text": "CRISPR Therapeutics AG (CRSP) is currently in an oversold technical position with an RSI of 26.28. The stock is trading below its 50-day and 200-day moving averages, indicating bearish momentum, though the oversold condition may suggest a potential for a bounce."
     }
    },
    {
     "@type": "Question",
     "name": "Are insiders buying or selling CRISPR Therapeutics AG stock?",
     "acceptedAnswer": {
      "@type": "Answer",
      "text": "Insiders at CRISPR Therapeutics AG are net buyers, having purchased $52.7 million worth of stock compared to $19.5 million in sales. This 'Moderate Buy Signal' suggests a positive sentiment from management regarding the company's future."
     }
    }
   ]
  }
 ]
}